Study:
A Phase I Trial of Tailored Radiation Therapy With Concomitant Cetuximab (C225, NSC #714692) and Cisplatin (NSC #119875) in the Treatment of Patients With Cervical Cancer
Rationale:
Monoclonal antibodies, such as cetuximab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such
as cisplatin, work in different ways to stop the growth of tumor cells, either by killing
the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays and
other types of radiation to kill tumor cells. Internal radiation therapy uses radioactive
material placed directly into or near a tumor to kill tumor cells. Giving cetuximab together
with cisplatin and radiation therapy may kill more tumor cells.
Purpose:
This phase I trial is studying the side effects and best dose of cetuximab when
given together with cisplatin and radiation therapy in treating patients with stage IB,
stage II, stage III, or stage IVA cervical cancer.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Cervical Cancer |
Biological: cetuximab
Drug: cisplatin
Radiation: brachytherapy
Radiation: radiation therapy |
Phase 1 |
Verified by
Gynecologic Oncology Group
October, 2011
Sponsored by: Gynecologic Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00104910
Study Type: Interventional
Study Design: Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
John H. Farley, MD., Study Chair
Russell J. Schilder, MD.,